51 related articles for article (PubMed ID: 16263739)
1. Baseline characteristics of an incident haemodialysis population in Spain: results from ANSWER--a multicentre, prospective, observational cohort study.
Pérez-García R; Martín-Malo A; Fort J; Cuevas X; Lladós F; Lozano J; García F;
Nephrol Dial Transplant; 2009 Feb; 24(2):578-88. PubMed ID: 19028750
[TBL] [Abstract][Full Text] [Related]
2. Hyperparathyroidism, Serum Phosphorus and Dietary Intake in Hemodialysis Patients: Is There a Novel Relationship?
Garagarza C; Valente A; Queirós C; Neto IP; Sebastião J; Gomes M; Ferreira A
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396685
[TBL] [Abstract][Full Text] [Related]
3. Could long-term dialysis vintage and abnormal calcium, phosphorus and iPTH control accelerate aging among the maintenance hemodialysis population?
Zhang Y; Yang H; Yang Z; Li X; Liu Z; Bai Y; Qian G; Wu H; Li J; Guo Y; Yang S; Chen L; Yang J; Han J; Ma S; Yang J; Yu L; Shui R; Jin X; Wang H; Zhang F; Chen T; Li X; Zong X; Liu L; Fan J; Wang W; Zhang Y; Shi G; Wang D; Tao S
Ren Fail; 2023; 45(2):2250457. PubMed ID: 37724516
[TBL] [Abstract][Full Text] [Related]
4. Gender and age differences in KDIGO treatment targets among people on maintenance hemodialysis: Findings from a tertiary hospital in Vietnam.
Pham HV; Tran NV; Thai TT; Tran HTB
Medicine (Baltimore); 2024 Jan; 103(4):e37088. PubMed ID: 38277525
[TBL] [Abstract][Full Text] [Related]
5. Association of calcium-phosphorus product with blood pressure in dialysis.
Ashkar ZM
J Clin Hypertens (Greenwich); 2010 Feb; 12(2):96-103. PubMed ID: 20167032
[TBL] [Abstract][Full Text] [Related]
6. Association of serum mineral parameters with mortality in hemodialysis patients: Data from the Korean end-stage renal disease registry.
Kim Y; Yoo KD; Kim HJ; Koh J; Yu Y; Kwon YJ; Kim GH; Yoo TH; Lee J; Jin DC; Choi BS; Kim YH; Oh KH
Kidney Res Clin Pract; 2018 Sep; 37(3):266-276. PubMed ID: 30254851
[TBL] [Abstract][Full Text] [Related]
7. Association of calciprotein particles with serum phosphorus among patients undergoing conventional and extended-hours haemodialysis.
Nishibori N; Okazaki M; Miura Y; Hishida M; Kurasawa S; Imaizumi T; Kato N; Kosugi T; Kuro-O M; Kasuga H; Kaneda F; Maruyama S
Clin Kidney J; 2024 Jun; 17(6):sfae121. PubMed ID: 38873576
[TBL] [Abstract][Full Text] [Related]
8. Managing chronic kidney disease - mineral bone disorder among patients on maintenance haemodialysis by achieving serum calcium and phosphate targets - a quality improvement project.
Surjit A; Moidu FM; Jegan C; Kuruvilla GG; Unni VN; Philips GM
Clin Med (Lond); 2023 Nov; 23(Suppl 6):123-124. PubMed ID: 38182231
[No Abstract] [Full Text] [Related]
9. A new paradigm for the treatment of secondary hyperparathyroidism.
de Francisco AL; Carrera F
NDT Plus; 2008 Jan; 1(Suppl 1):i24-i28. PubMed ID: 25983953
[TBL] [Abstract][Full Text] [Related]
10. Clinical usefulness of lanthanum carbonate for serum phosphate control in difficult patients.
Almirall J; Betancourt L; Esteve V; Valenzuela MP; López T; Ruiz A; Martínez-Ocaña JC; Calvet X
Int Urol Nephrol; 2012 Feb; 44(1):231-6. PubMed ID: 21069570
[TBL] [Abstract][Full Text] [Related]
11. Public health approach to addressing hyperphosphatemia among dialysis patients.
Sehgal AR; Sullivan C; Leon JB; Bialostosky K
J Ren Nutr; 2008 May; 18(3):256-61. PubMed ID: 18410881
[TBL] [Abstract][Full Text] [Related]
12. Phosphorus-containing food additives and the accuracy of nutrient databases: implications for renal patients.
Sullivan CM; Leon JB; Sehgal AR
J Ren Nutr; 2007 Sep; 17(5):350-4. PubMed ID: 17720105
[TBL] [Abstract][Full Text] [Related]
13. Extended release nicotinic acid - a novel oral agent for phosphate control.
Sampathkumar K; Selvam M; Sooraj YS; Gowthaman S; Ajeshkumar RN
Int Urol Nephrol; 2006; 38(1):171-4. PubMed ID: 16502077
[TBL] [Abstract][Full Text] [Related]
14. Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study.
Lorenzo V; Martin-Malo A; Perez-Garcia R; Torregrosa JV; Vega N; de Francisco AL; Cases A
Nephrol Dial Transplant; 2006 Feb; 21(2):459-65. PubMed ID: 16263739
[TBL] [Abstract][Full Text] [Related]
15. Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia.
Maduell F; Gorriz JL; Pallardo LM; Pons R; Santiago C;
J Nephrol; 2005; 18(6):739-48. PubMed ID: 16358233
[TBL] [Abstract][Full Text] [Related]
16. Mineral metabolism and haemoglobin concentration among haemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Kimata N; Akiba T; Pisoni RL; Albert JM; Satayathum S; Cruz JM; Akizawa T; Andreucci VE; Young EW; Port FK
Nephrol Dial Transplant; 2005 May; 20(5):927-35. PubMed ID: 15728270
[TBL] [Abstract][Full Text] [Related]
17. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units.
Arenas MD; Alvarez-Ude F; Gil MT; Soriano A; Egea JJ; Millán I; Amoedo ML; Muray S; Carretón MA
Nephrol Dial Transplant; 2006 Jun; 21(6):1663-8. PubMed ID: 16464885
[TBL] [Abstract][Full Text] [Related]
18. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
19. Phosphate binder therapy for attainment of K/DOQI bone metabolism guidelines.
Nolan CR
Kidney Int Suppl; 2005 Jul; (96):S7-14. PubMed ID: 15954948
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
